26,927 findings
- NeuralStrong
The incidence of peripheral neuropathy (PN) differs by type 2 diabetes (T2D) subgroup.
Healthcare providers should consider T2D subgroups when assessing PN risk.
Supports 2026New - MixedStrong
Handgrip strength reference ranges vary significantly by geographic region and ethnicity, meaning a single global standard is invalid for clinical risk stratification.
If you are using handgrip strength to assess your health or frailty risk, do not compare your score to a generic global chart. Your 'normal' depends heavily on your geographic region and ethnicity. Use region-specific reference ranges to accurately interpret your strength levels, as values in South Asia or Africa are naturally lower than those in Europe or North America.
Qualifies 2016 - HormonalStrong
Long-term metformin (850 mg twice daily) and intensive lifestyle interventions do not reduce major cardiovascular events in individuals with prediabetes, despite significantly delaying or preventing the onset of type 2 diabetes.
Taking metformin or following a strict lifestyle program to prevent diabetes does not guarantee protection against heart attacks or strokes, even if you successfully avoid developing diabetes. In this long-term study, these interventions prevented diabetes but did not lower cardiovascular event rates compared to placebo, likely because other risk factors (blood pressure, cholesterol) were managed by standard care. Focus on comprehensive risk management, not just glucose control.
Refutes 2022 - HormonalStrong
Statin therapy causes a moderate, dose-dependent increase in the diagnosis of new-onset diabetes and worsening glycaemia, with high-intensity regimens producing a 36% relative increase compared to a 10% increase for low/moderate-intensity regimens.
If you are taking statins, be aware that they can slightly raise your blood sugar, especially at higher doses. This increases your risk of being diagnosed with diabetes, particularly if your blood sugar was already near the threshold. However, the heart protection benefits of statins far outweigh this small risk. Regular monitoring of your blood sugar is recommended.
Supports 2024 - HormonalStrong
The absolute excess risk of new-onset diabetes from statins is highest in individuals whose baseline glycaemic markers are already close to the diagnostic threshold for diabetes.
If you have pre-diabetes or high-normal blood sugar, your risk of developing diabetes while on statins is higher than someone with normal blood sugar. This does not mean you should stop the statin, but it does mean you should monitor your blood sugar more closely and focus on lifestyle changes to keep your blood sugar in check.
Qualifies 2024 - HormonalStrong
Acute exercise triggers a redistribution of blood flow and metabolic substrate utilization across organs, with increased perfusion to working muscles and brain areas controlling movement, while vasoconstriction occurs in visceral organs.
During exercise, your body prioritizes blood flow to your muscles and active brain regions. This is a normal and necessary physiological response that ensures working tissues receive enough oxygen and nutrients.
Supports 2014 - HormonalStrong
Visceral feedback from the gut activates GCG neurons in the cNTS to promote long-lasting satiety (tens of minutes) that tracks cumulative food intake.
The physical presence of food in your stomach and intestines activates GCG neurons, which promote a feeling of fullness that lasts for tens of minutes. This visceral feedback tracks how much you have eaten, contributing to long-lasting satiety after a meal.
Supports 2023 - HormonalStrong
Rare deleterious variants in six specific effector genes (MC4R, PCSK1, POMC, CALCR, BSN, and CORO1A) are significantly associated with BMI at the population level, with CORO1A being a newly identified genetic risk factor for obesity.
Genetic testing can identify individuals with rare variants in genes like CORO1A, MC4R, or PCSK1 who are at higher risk for severe obesity. Knowing this early can guide personalized prevention strategies, such as early lifestyle interventions or targeted pharmacological therapies, before significant weight gain occurs.
Supports 2025New - MixedStrong
Genetic variants (SNPs) associated with obesity, diabetes, and cardiovascular disease generally have small effect sizes and explain a small fraction of the overall variance in these conditions.
Understanding your genetics does not give you a free pass or a guaranteed outcome. Most genetic risks are small and can be managed. Focus on modifiable risk factors like BMI, blood pressure, and diet quality.
Qualifies 2022 - MixedStrong
Implementation of Enhanced Recovery After Surgery (ERAS) protocols in bariatric surgery significantly reduces postoperative nausea and vomiting, intraoperative time, time to mobilization, intensive care unit stay, and total/functional hospital stay compared to standard care, without increasing complication rates.
For bariatric surgery units, adopting ERAS protocols is a high-value intervention. It significantly reduces patient suffering (nausea/vomiting), shortens hospital stays, and speeds up mobilization without increasing surgical risks like leaks or bleeding. Implementation should be prioritized where feasible.
Supports 2024 - HormonalStrong
Race and geographic region significantly modify the risk of new-onset diabetes in people with HIV, with higher rates observed in South Asia and among Black or African American individuals in high-income regions.
If you are from South Asia or are Black/African American, you may have a higher baseline risk for diabetes. Work with your healthcare provider to monitor your blood sugar and weight closely, as these risks can be managed with lifestyle changes.
Supports 2024 - HormonalStrong
SGLT-2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) reduce cardiovascular death and heart failure hospitalizations in patients with type 2 diabetes, heart failure, or chronic kidney disease, regardless of baseline glycemic control.
If you have heart failure, kidney disease, or high-risk diabetes, ask your doctor about SGLT-2 inhibitors (like Jardiance, Farxiga, or Invokana). These drugs protect your heart and kidneys, not just your blood sugar. The benefits are proven to reduce hospital stays and death, even if your blood sugar is already well-controlled.
Supports 2021 - HormonalStrong
Existing FDA-approved smoking cessation medications (varenicline, nicotine replacement therapy, and bupropion alone) provide only modest attenuation of post-cessation weight gain and do not eliminate it.
Standard smoking cessation drugs like patches, gum, or varenicline will help you quit, but they are not designed to stop you from gaining weight afterward. Expect modest weight changes, but do not rely on them to maintain your weight.
Refutes 2025New - HormonalStrong
Aggressive blood glucose lowering (targeting HbA1c < 6.5%) in type 2 diabetes does not necessarily reduce cardiovascular risk and may increase overall mortality due to side effects like hypoglycemia and weight gain.
Do not aim for an HbA1c below 6.5% if it requires strong medications that cause low blood sugar or weight gain. The goal is stable, safe blood sugar levels, not the lowest possible number.
Refutes 2020 - HormonalStrong
SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, sotagliflozin) significantly reduce major adverse cardiovascular events (MACE-3), cardiovascular death, and heart failure hospitalizations in patients with type 2 diabetes and established cardiovascular disease, independent of glycemic control.
If you have Type 2 Diabetes and heart disease or heart failure, SGLT2 inhibitors are a first-line treatment option that protects your heart and reduces hospitalization risk, regardless of your blood sugar levels. Consult your doctor about these specific medications.
Supports 2022 - Energy balanceStrong
Common obesity is primarily driven by increased energy intake due to a changing food environment overwhelming homeostatic feedback, rather than defective homeostatic regulation.
Focus on the food environment and intake rather than just blaming willpower or assuming a broken metabolism. The primary driver of the obesity epidemic is increased food intake due to a changing food environment.
Supports 2014 - HormonalStrong
Bariatric surgery significantly reduces the incidence of mortality and cardiovascular diseases compared to best non-surgical care in patients with obesity.
Bariatric surgery offers a dramatic reduction in mortality and cardiovascular disease risk compared to non-surgical weight loss methods. For patients with obesity, surgery is the most effective intervention for long-term survival and cardiovascular health.
Supports 2022 - Micronutrients & recoveryStrong
Dietary self-report instruments (FFQs and 24-hour recalls) significantly underestimate sodium intake (by 23-52% for FFQs and 23-28% for 24HRs), whereas potassium intake is captured with much higher accuracy (underreporting of only 5-6% for FFQs).
If you are tracking sodium for health reasons, do not rely solely on your memory or standard food diaries, as you will likely underestimate your intake by 25-50%. To get a more accurate picture, use multiple 24-hour recalls (averaging 3 is best) or focus on the Sodium:Potassium ratio, which is measured more accurately than sodium alone. For potassium, self-reports are reasonably accurate.
Qualifies 2015 - MixedStrong
The metabolic syndrome is a cluster of risk factors that identifies individuals at increased lifetime risk for atherosclerotic cardiovascular disease (ASCVD) and type 2 diabetes, but it is not an adequate tool for estimating short-term (10-year) cardiovascular risk.
Having metabolic syndrome means you are at higher risk for heart disease and diabetes over your lifetime, but it does not mean you will have a heart attack soon. Use standard risk calculators (like Framingham) to check your 10-year risk. Focus on lifestyle changes to lower your long-term risk, especially if you do not yet have diabetes.
Qualifies 2005 - HormonalStrong
Insulin resistance and impaired insulin secretion are the primary physiological precursors to the development of non-insulin-dependent diabetes mellitus (NIDDM), with insulin resistance preceding hyperinsulinemia and hyperglycemia.
Diabetes risk is driven by how your body handles insulin, not just blood sugar levels. If you have a family history or risk factors, prioritize improving insulin sensitivity through regular physical activity and maintaining a healthy weight, as these factors precede the onset of high blood sugar.
Supports 1993 - HormonalStrong
Natural menopause is associated with a significantly increased risk of coronary heart disease in women, with the risk rising sharply in the years immediately following menopause.
After menopause, your risk of heart disease rises significantly. This is a biological shift, not just aging. Prioritize heart-healthy habits like regular exercise, a balanced diet, and regular check-ups to manage this increased risk proactively.
Supports 1987 - HormonalStrong
High intake of seafood is associated with a significantly increased risk of gout, with the effect being stronger in men with a body mass index (BMI) less than 25 compared to those with a BMI of 25 or higher.
For men with gout, avoiding seafood is generally recommended. However, this risk appears to be particularly pronounced in men who are not overweight (BMI < 25). If you are overweight, the link between seafood and gout may be less distinct, though avoidance is still prudent. Focus on meat and seafood reduction as primary dietary levers.
Qualifies 2004 - HormonalStrong
Consumption of purine-rich vegetables (peas, beans, lentils, spinach, mushrooms, oatmeal, cauliflower) is not associated with an increased risk of gout.
You do not need to restrict purine-rich vegetables such as spinach, mushrooms, beans, or lentils if you have gout. Unlike meat and seafood, these plant-based foods do not appear to increase your risk of gout attacks.
Refutes 2004 - MixedStrong
Cardiovascular-Kidney-Metabolic (CKM) syndrome is a systemic disorder characterized by pathophysiological interactions among metabolic risk factors, chronic kidney disease (CKD), and the cardiovascular system, leading to multiorgan dysfunction and high adverse outcome rates.
If you have high blood pressure, diabetes, or kidney issues, recognize that these conditions are linked and worsen each other. Managing one without addressing the others is less effective. Seek integrated care that looks at your heart, kidneys, and metabolic health together to prevent serious complications like heart failure or kidney failure.
Supports 2023